Lutetium
lanthanideProperties
| Property | Value |
|---|---|
| Atomic Mass | 174.97 amu |
| Category | lanthanide |
| Period | 6 |
| Electron Configuration | [Xe] 4f14 5d1 6s2 |
| Electronegativity | 1.27 (Pauling) |
| Oxidation States | 3 |
| Melting Point | 1925 K (1651.8 °C) |
| Boiling Point | 3675 K (3401.8 °C) |
| Density | 9.841 g/cm³ |
| Discovered By | Georges Urbain, Carl Auer von Welsbach (1907) |
About Lutetium
Lutetium closes the lanthanide row — atomic number 71, named after Lutetia, the Roman name for Paris. It is the densest and hardest of the rare earths (9.84 g/cm³) and was the last naturally occurring lanthanide to be isolated, which Urbain, Auer von Welsbach, and Charles James all managed independently in 1907. The 4f shell is full (4f¹⁴), so unlike its lighter neighbors Lu has no f-orbital contribution to its bonding and behaves much more like a group 3 transition metal than a textbook lanthanide. That distinction matters in modern uses. Lutetium oxyorthosilicate (LSO) and its cerium-doped variant LYSO are the preferred scintillator crystals in clinical PET scanners — they have short decay times (~40 ns) and high light yield, which translates to sharper images at lower doses. The bigger story right now is Lu-177, a beta emitter with a 6.65-day half-life: chelated to a tumor-targeting peptide it became the active ingredient in Lutathera (for neuroendocrine tumors) and Pluvicto (for metastatic prostate cancer), turning a once-obscure rare earth into a frontline radiopharmaceutical.
Fun Fact
Lutetium-177 is revolutionizing cancer treatment — this radioactive isotope can be attached to molecules that seek out cancer cells, delivering lethal radiation directly to tumors while sparing healthy tissue.
Common Uses
- Scintillator crystals (LSO, LYSO) in clinical PET scanners
- Lu-177 radiopharmaceuticals for neuroendocrine and prostate cancer
- Petroleum cracking and hydrogenation catalysts
- High-refractive-index lens glass
- Lu-Hf radiometric dating of zircons and meteorites